Skip to main navigation Skip to search Skip to main content

Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion cohort

  • Laura Q.M. Chow
  • , Robert Haddad
  • , Shilpa Gupta
  • , Amit Mahipal
  • , Ranee Mehra
  • , Makoto Tahara
  • , Raanan Berger
  • , Joseph Paul Eder
  • , Barbara Burtness
  • , Se Hoon Lee
  • , Bhumsuk Keam
  • , Hyunseok Kang
  • , Kei Muro
  • , Jared Weiss
  • , Ravit Geva
  • , Chia Chi Lin
  • , Hyun Cheol Chung
  • , Amy Meister
  • , Marisa Dolled-Filhart
  • , Kumudu Pathiraja
    • Jonathan D. Cheng, Tanguy Y. Seiwert
  • University of Washington
  • Dana-Farber Cancer Institute
  • Moffitt Cancer Center
  • Fox Chase Cancer Center
  • National Cancer Center Japan
  • Sheba Medical Center at Tel Hashomer
  • Yale University
  • Seoul National University
  • Johns Hopkins University
  • Aichi Cancer Center Hospital and Research Institute
  • University of North Carolina at Chapel Hill
  • Tel Aviv Sourasky Medical Center
  • National Taiwan University
  • Yonsei University
  • Merck
  • The University of Chicago

Research output: Contribution to journal › Article › peer-review

766   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion cohort'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science